Medtronic Completes High Risk Patient Enrollment in CoreValveR U.S. Pivotal Trial and Gains FDA Approval to Study Intermediate Risk Patients in Global SURTAVI Trial

Wed Aug 29, 2012 9:00am EDT

* Reuters is not responsible for the content in this press release.

Medtronic, Inc.

MINNEAPOLIS - August 29, 2012 - Medtronic, Inc. (NYSE: MDT) has reached two clinical program milestones for its CoreValveR System in the United States. First, it completed enrollment in its study of high risk patients in its CoreValveR U.S. Pivotal Trial, which concludes the total Trial enrollment of more than 1,500 patients with severe aortic stenosis who are at high or extreme risk for aortic valve surgery. Medtronic continues to enroll extreme risk patients in the Trial as part of the U.S. Food and Drug Administration (FDA) Continued Access Policy and is seeking approval to continue enrolling high risk patients under this policy.

In addition, Medtronic received FDA conditional approval to begin evaluating the CoreValve System in patients at intermediate risk for open-heart aortic valve replacement as part of the Medtronic CoreValve Surgical Replacement and Transcatheter Aortic Valve Implantation (SURTAVI) Trial. U.S. patient enrollment is expected to begin within weeks.

"With a sizeable population of Americans with severe aortic stenosis who have varying degrees of risk for open-heart aortic valve replacement surgery, the CoreValve U.S. Pivotal Trial and SURTAVI Trial are landmark trials that will provide critical insights about the appropriate use of the self-expanding CoreValve System," said David H. Adams, M.D., chair of the Department of Cardiothoracic Surgery at The Mount Sinai Medical Center and national co-principal investigator of both the CoreValve U.S. Pivotal Trial and SURTAVI Trial. "We are optimistic and eager to fulfill the requirements of both trials with the goal of effectively demonstrating the value of CoreValve as an alternative to open-heart valve replacement surgery."

About the Medtronic CoreValve U.S. Pivotal Trial
The CoreValve U.S. Pivotal Trial has enrolled more than 1,500 patients in two studies (high and extreme risk) led by heart teams made up of interventional cardiologists and cardiac surgeons at 45 leading clinical institutions across the U.S. Approximately two-thirds of Trial patients are in the high risk study. The primary endpoint for the high risk study is freedom from all-cause death at 12 months, and the primary endpoint for the extreme risk study is freedom from all-cause death or major stroke within 12 months.

About the Medtronic SURTAVI Trial
The SURTAVI Trial is the largest global, randomized, controlled trial on transcatheter aortic valve implantation (TAVI) and will evaluate approximately 2,500 patients. The Trial will evaluate the potential for the minimally-invasive CoreValve System to be considered for less-sick patients who typically are treated with open-heart surgical aortic valve replacement today (SAVR). Within the SURTAVI Trial, CoreValve implantation can be performed by transfemoral, subclavian or direct aortic access, depending on the needs of the patient. Selection of intermediate risk surgical patients will be based on the Society of Thoracic Surgeons (STS) mortality risk of ≥4 percent and ≤10 percent and the study's primary endpoint will be a composite of all-cause mortality and disabling stroke at 24 months. All patients will be followed through five years. U.S. principal investigators are Dr. Adams; Jeffrey Popma, M.D., director, Interventional Cardiology at the Beth Israel Deaconess Medical Center in Boston; and Michael Reardon, M.D., chief of cardiac surgery at the Methodist DeBakey Heart & Vascular Center in Houston.

Since 2007, the Medtronic CoreValve System has been implanted in more than 30,000 people in more than 60 countries outside the U.S. Additional information about the U.S. Pivotal Trial and SURTAVI Trial is available on www.clinicaltrials.gov. The Medtronic CoreValve System is available in the United States for investigational use only.

In collaboration with leading clinicians, researchers and scientists worldwide, Medtronic offers the broadest range of innovative medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias.

About Medtronic
Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology - alleviating pain, restoring health, and extending life for millions of people around the world.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

- end -

Contacts:
Kathleen Janasz
Public Relations
+1-763-526-3676

Jeff Warren
Investor Relations
+1-763-505-2696





This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Medtronic, Inc. via Thomson Reuters ONE

HUG#1636552